Non-immunosuppressive treatment for IgA nephropathy
(Review)

Reid S, Cawthon PM, Craig JC, Samuels JA, Molony DA, Strippoli GFM

This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2011, Issue 3

http://www.thecochranelibrary.com

WILEY
Non-immunosuppressive treatment for IgA nephropathy

Sharon Reid¹, Peggy M Cawthon², Jonathan C Craig³, Joshua A Samuels⁴, Donald A Molony⁵, Giovanni FM Strippoli⁶

¹Sydney School of Public Health, University of Sydney, Sydney, Australia. ²Research Institute, California Pacific Medical Center, San Francisco, CA, USA. ³a) Cochrane Renal Group, Centre for Kidney Research, The Children's Hospital at Westmead, b) Sydney School of Public Health, The University of Sydney, Sydney, Australia. ⁴Nephrology / Pediatric Nephrology, UT-Houston Health Science Center, Houston, TX, USA. ⁵Internal Medicine, UT-Houston Health Science Center, Houston, TX, USA. ⁶a) Mario Negri Sud Consortium, Santa Maria Imbaro (Ch), Italy, b) Sydney School of Public Health, University of Sydney, Australia, c) Diaverum Medical-Scientific Office, Lund, Sweden

Contact address: Giovanni FM Strippoli, Cochrane Renal Group, The Children's Hospital at Westmead, Locked Bag 4001, Westmead, NSW, 2145, Australia. Giovanni.Strippoli@diaverum.com. strippoli@negrisud.it.

Editorial group: Cochrane Renal Group.
Review content assessed as up-to-date: 13 July 2010.

Citation: Reid S, Cawthon PM, Craig JC, Samuels JA, Molony DA, Strippoli GFM. Non-immunosuppressive treatment for IgA nephropathy. Cochrane Database of Systematic Reviews 2011, Issue 3. Art. No.: CD003962. DOI: 10.1002/14651858.CD003962.pub2.

Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

Background
IgA nephropathy (IgAN) is the most common primary glomerular disease with approximately 30% to 40% of patients progressing to end-stage kidney disease (ESKD) within 20 years. The most common regimens include immunosuppressive agents, however the risks of long-term treatment often outweigh the potential benefits. Non-immunosuppressive options, including fish oils, anticoagulants, antihypertensive agents and tonsillectomy have also been examined but not reviewed systematically.

Objectives
To assess the benefits and harms of non-immunosuppressive treatments for treating IgAN in adults and children.

Search methods
In July 2010 we searched the Cochrane Renal Group’s specialised register, CENTRAL (in The Cochrane Library), MEDLINE (from 1966) and EMBASE (from 1980). We also searched reference lists of included studies, review articles and contacted local and international experts.

Selection criteria
Randomised controlled trials (RCTs) of non-immunosuppressive agents in adults and children with biopsy-proven IgAN were included.

Data collection and analysis
Two authors independently reviewed search results, extracted data and assessed study quality. Results were expressed as mean differences (MD) for continuous outcomes and risk ratios (RR) for dichotomous outcomes with 95% confidence intervals (CI) using a random-effects model.
Main results

We included 56 studies (2838 participants). Antihypertensive agents were the most beneficial non-immunosuppressive intervention for IgAN. The antihypertensives examined were predominantly angiotensin-converting enzyme inhibitors (ACEi), angiotensin receptor blockers (ARB) or combinations of both, versus other antihypertensives and other agents. The benefits of antihypertensive agents, particularly inhibitors of the renin angiotensin system, appear to potentially outweigh the harms in patients with IgAN. The benefits are largely manifest as a reduction in proteinuria, a surrogate outcome. There is no evidence that treatment with any of the antihypertensive agents evaluated affect major renal and/or cardiovascular endpoints or long-term mortality risk beyond the benefit that arises from controlling hypertension in patients with IgAN. The RCT evidence is insufficiently robust to demonstrate efficacy for any of the other non-immunosuppressive therapies evaluated here.

Authors’ conclusions

IgAN remains a disease in search of adequately powered RCTs to reliably inform clinical practice. More and better evidence is needed to understand the magnitude of benefit and the possible risks of anti-hypertensive or more specifically of ACEi/ARB therapy alone or in combination and which specific types of patients with the IgAN might have the greatest potential for benefit. For other non-immunosuppressive therapies, where neither benefit nor significant harm has yet to be demonstrated, there remains some justification for further exploration of the potential benefits.

Plain Language Summary

Non-immunosuppressive treatment for IgA nephropathy

IgA nephropathy (IgAN) is the most common primary glomerular disease with approximately 30% to 40% of patients progressing to end-stage kidney disease (ESKD) within 20 years. The most common regimens include immunosuppressive agents, however the risks of long-term treatment often outweigh the potential benefits. Non-immunosuppressive options, including fish oils, anticoagulants, antihypertensive agents and tonsillectomy have also been examined but not reviewed systematically.

We included 56 studies enrolling 2838 participants. Antihypertensive agents were the most beneficial non-immunosuppressive intervention for IgAN. The antihypertensives examined here were predominantly angiotensin-converting enzyme inhibitors (ACEi), angiotensin receptor blockers (ARB) or combinations of both, compared with other antihypertensives and other agents. The benefits of antihypertensive agents appear to potentially outweigh the harms in patients with IgAN. The benefits were mostly reported as a reduction in 24 hour proteinuria. There is no evidence that treatment with any of the antihypertensive agents evaluated to date affect major renal and/or cardiovascular endpoints or long-term mortality risk beyond the benefit that arises from controlling hypertension in patients with IgAN. The RCT evidence is insufficiently robust to demonstrate efficacy for any of the other non-immunosuppressive therapies evaluated here.

IgAN remains a disease in search of adequately powered RCTs to reliably inform clinical practice. More and better evidence is needed to understand the magnitude of benefit and the possible risks of anti-hypertensive or more specifically of ACEi/ARB therapy alone or in combination and which specific types of patients with the IgAN might have the greatest potential for benefit. For other non-immunosuppressive therapies, where neither benefit nor significant harm has yet to be demonstrated, there remains some justification for further exploration of the potential benefits.